Emerging Trends and Debates in Breast Cancer: Impact of Research on Surgical Strategies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 1689

Special Issue Editors


E-Mail Website
Guest Editor
Multidisciplinary Breast Center, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Interests: breast cancer; breast pathology; breast reconstruction; breast surgery; contralateral prophylactic mastectomy; mastectomy; oncoplastic surgery; surgical oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Multidisciplinary Breast Center, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Interests: breast cancer; oncoplastic breast surgery; conservative mastectomy; conservative breast surgery; prepectoral breast reconstruction; surgical oncology

E-Mail Website
Guest Editor
Multidisciplinary Breast Center, Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Interests: breast cancer; breast pathology; breast reconstruction; breast surgery; contralateral prophylactic mastectomy; mastectomy; oncoplastic surgery; surgical oncology

Special Issue Information

Dear Colleagues,

Breast cancer remains a significant health challenge globally, and surgical treatment plays a crucial role in its management. This Special Issue aims to provide a comprehensive overview of the latest advancements, techniques, and controversies in the surgical management of breast tumors.

Through a combination of original research articles, reviews, etc., this Special Issue aims to delve into the various aspects of breast cancer surgery, including breast-conserving surgery in selected patients, conservative mastectomy and prepectoral breast reconstruction, minimally invasive surgery, oncoplastic techniques, axillary lymph node de-escalation treatment, intraoperative imaging margin assessment, and the management of lesions of uncertain malignant potential in the breast (B3).

Additionally, we aim to explore the emerging trends in surgical oncology, such as minimally invasive approaches, targeted therapies, and personalized treatment strategies with a focus on controversial situations.

Therefore, researchers in the field of breast surgery, breast oncology, and surgical oncology are encouraged to submit and share their insights, experiences, and innovations in breast cancer surgery.

Dr. Alejandro Martin Sanchez
Dr. Lorenzo Scardina
Dr. Sabatino D'Archi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • breast tumors
  • breast reconstruction
  • breast surgery

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1977 KiB  
Article
Young Women with Early-Stage Breast Cancer Treated with Upfront Surgery: Overview of Oncological Outcomes
by Lorenzo Scardina, Beatrice Carnassale, Alba Di Leone, Alejandro Martin Sanchez, Ersilia Biondi, Francesca Moschella, Sabatino D’Archi, Antonio Franco, Flavia De Lauretis, Enrico Di Guglielmo, Eleonora Petrazzuolo, Stefano Magno, Riccardo Masetti and Gianluca Franceschini
J. Clin. Med. 2024, 13(13), 3966; https://doi.org/10.3390/jcm13133966 - 6 Jul 2024
Viewed by 482
Abstract
Background: Breast cancer in young women aged < 40 years is rare and often aggressive with less favorable survival rates. The lack of systematic screening, later stage at diagnosis, and a more aggressive disease biology may all contribute to their poor prognosis. [...] Read more.
Background: Breast cancer in young women aged < 40 years is rare and often aggressive with less favorable survival rates. The lack of systematic screening, later stage at diagnosis, and a more aggressive disease biology may all contribute to their poor prognosis. Data on the best management remain conflicting, especially those regarding surgical management, either breast-conserving or mastectomy. To our knowledge, there are limited studies surrounding the treatment of young women with early breast cancer, and this analysis evaluated the oncological outcomes for those patients who underwent surgery upfront. Methods: We conducted a retrospective study including 130 young women with early breast cancer from a total of 373 consecutive patients treated with upfront surgery between January 2016 and December 2021 at our institution. Local recurrence-free survival (LR-FS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were evaluated. Results: The median follow-up was 61.1 months (range, 25–95). A total of 92 (70.8%) patients underwent breast-conserving surgery, while 38 (29.2%) patients underwent conservative mastectomy with immediate implant breast reconstruction. In total, 8 of 130 patients (6.2%) developed a local recurrence in the treated breast, an7 (5.4%) patients presented distant metastasis. Overall, two (1.6%) patients died due to breast cancer recurrence. Conclusions: The results of our study interestingly support breast-conserving surgery in young patients with early-stage breast cancer. While appropriate breast-conserving surgery can achieve favorable oncological outcomes and can always be considered a valid alternative to conservative mastectomy in upfront surgery, a younger age at diagnosis should never be used alone to choose the type of surgery. Full article
Show Figures

Figure 1

15 pages, 1770 KiB  
Article
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience
by Alejandro M. Sanchez, Flavia De Lauretis, Angela Bucaro, Niccolo Borghesan, Chiara V. Pirrottina, Antonio Franco, Lorenzo Scardina, Diana Giannarelli, Jenny C. Millochau, Marina L. Parapini, Alba Di Leone, Fabio Marazzi, Armando Orlandi, Antonella Palazzo, Alessandra Fabi, Riccardo Masetti and Gianluca Franceschini
J. Clin. Med. 2024, 13(13), 3665; https://doi.org/10.3390/jcm13133665 - 23 Jun 2024
Viewed by 945
Abstract
Background: Oncoplastic surgery (OPS) reliability in the post-neoadjuvant chemotherapy (NACT) setting is still debated due to weak scientific evidences in such scenarios. Methods: Our analysis aims to report results obtained in a retrospective series of 111 patients consecutively treated with level II OPS [...] Read more.
Background: Oncoplastic surgery (OPS) reliability in the post-neoadjuvant chemotherapy (NACT) setting is still debated due to weak scientific evidences in such scenarios. Methods: Our analysis aims to report results obtained in a retrospective series of 111 patients consecutively treated with level II OPS after NACT at the Multidisciplinary Breast Center of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS between 1998 and 2018. The surgical endpoints were the mean specimen volume, rates of positive margins (PMR), re-excision (RR), conversion to mastectomy (CMR), and complications (CR). The oncological endpoints were overall survival (OS), disease-free survival (DFS), and local recurrence (LR). To evaluate the impact of NACT on surgical and oncological outcomes at 302 months, we conducted a propensity score matching, pairing patients in post-NACT and upfront surgery groups. Results: The mean sample volume was 390,796 mm3. We registered a 3.6% of PMR, 1.8% RR, 0.9% CMR, 5% CR. The 10-year OS and 10-year DFS with a median follow-up of 88 months (6–302) were 79% and 76%, respectively, with an LR recurrence rate of 5%. The post-NACT group received significantly larger excised volumes and lower PMR. NACT did not affect surgical and oncological outcomes. Conclusions: Level II OPS can be considered a reliable alternative to mastectomy even in the post-NACT setting. Full article
Show Figures

Figure 1

Back to TopTop